Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
76 participants
INTERVENTIONAL
2012-06-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Neurocognitive Sub-study of Encore1
NCT01516060
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
NCT02674581
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
NCT04303156
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
NCT00106379
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
NCT00703586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NRTI + PI
arm 1
arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
NRTI + PI
PI + maraviroc
arm 2
Arm 2 boosted protease inhibitors and maraviroc
PI + maraviroc
NRTI + maraviroc
arm 3
Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
NRTI + maraviroc
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
NRTI + PI
Arm 2 boosted protease inhibitors and maraviroc
PI + maraviroc
Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
NRTI + maraviroc
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Enrolled into the substudy either at or before the week 0 visit of the main study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kirby Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Waldo Belloso, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Italiano de Buenos Aires
Mark Kelly, MD
Role: PRINCIPAL_INVESTIGATOR
Brisbane Sexual Health and HIV Service
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires F.D., Argentina
Hospital General de Agudos J M Ramos Mejia
Buenos Aires, Buenos Aires F.D., Argentina
Fundación IDEAA
Buenos Aires, Buenos Aires F.D., Argentina
St. Vincent's Hospital
Sydney, New South Wales, Australia
Brisbane Sexual Health and HIV Service
Brisbane, Queensland, Australia
Southern Alberta Clinic
Calgary, Alberta, Canada
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada
Clinic Opus/Lori
Montreal, Quebec, Canada
Klinikum der Universitat Zu Koln
Cologne, , Germany
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, MX-Ambulanz
Düsseldorf, , Germany
Nagoya Medical Center
Nagoya, , Japan
Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran
Mexico City, Tlalpan DF, Mexico
Chulalongkorn University Hospital
Bangkok, , Thailand
Western General Hospital
Edinburgh, Lothian, United Kingdom
Brighton & Sussex University NHS Trust
Brighton, Sussex, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MARCH-Kirby renal
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.